Kura Oncology Launches $50 Million Subsidiary to Advance Menin Inhibition Strategy in Diabetes
Kura Oncology (NASDAQ: KURA) has announced the launch of Caspian Therapeutics, a new subsidiary backed by a $50 million financing round led by BVF Partners and including participation from Eli Lilly (NYSE: LLY), Invus, Montanova, T1D Fund, and other investors. The funding aims to advance KO-7246, Kura's next-generation menin inhibitor designed for chronic metabolic diseases such as diabetes. Caspian will operate independently with its own leadership but will have access to Kura’s research capabilities under an intercompany services agreement. Kura retains approximately 50% ownership and board representation in the new entity. The financing is expected to support IND-enabling development of KO-7246, initial clinical trials for diabetes, as well as a second menin inhibitor candidate. Analysts have maintained or upgraded their ratings on KURA stock recently, with Wedbush raising its price target significantly and Citizens maintaining an Outperform rating. Despite the positive analyst sentiment, shares were down slightly at $12.39 during publication.
